Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $1,105,992.72 in Stock

Key Points

• Nikita Shah, EVP of Amneal Pharmaceuticals, sold 114,492 shares worth $1,105,992.72, reducing his ownership by 42.84% to 152,743 shares valued at $1,475,497.38.
• Amneal Pharmaceuticals experienced a stock decline of 3.2%, with shares trading at $9.28 and a trading volume of 1,111,483 shares.
• The company reported $0.23 EPS for the last quarter, beating estimates, and has set FY 2025 guidance at 0.700-0.750 EPS.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 114,492 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $9.66, for a total value of $1,105,992.72. Following the sale, the executive vice president directly owned 152,743 shares in the company, valued at $1,475,497.38. This trade represents a 42.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Nikita Shah also recently made the following trade(s):

• On Monday, August 25th, Nikita Shah sold 6,340 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.50, for a total transaction of $60,230.00.
• On Thursday, August 14th, Nikita Shah sold 71,694 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $9.29, for a total transaction of $666,037.26.
• On Tuesday, August 12th, Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $9.04, for a total transaction of $452,000.00.

Amneal Pharmaceuticals Stock Down 3.2%

AMRX traded down $0.31 on Monday, hitting $9.28. The company had a trading volume of 1,111,483 shares, compared to its average volume of 1,684,684. The business's fifty day simple moving average is $8.38 and its 200 day simple moving average is $8.01. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $9.79. The company has a market cap of $2.91 billion, a PE ratio of 928.93 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. The Goldman Sachs Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price objective for the company. Wall Street Zen cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $11.60.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Amneal Pharmaceuticals by 5,975.0% in the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after buying an additional 3,107 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $31,000. Amalgamated Bank boosted its holdings in shares of Amneal Pharmaceuticals by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares during the period. GF Fund Management CO. LTD. bought a new position in Amneal Pharmaceuticals in the fourth quarter worth approximately $52,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Amneal Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock worth $98,000 after purchasing an additional 1,735 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.